The National Alliance of Advocates
for Buprenorphine Treatment

Buprenorphine (Suboxone®, Subutex®3, Zubsolv™4, Bunavail™5) is an opioid medication used to treat opioid addiction in the privacy of a physician's office.1 Buprenorphine can be dispensed for take-home use, by prescription.1 This, in addition to the pharmacological and safety profile of buprenorphine, makes it an attractive treatment for patients addicted to opioids.2

About Us


DonateThe National Alliance of Advocates for Buprenorphine Treatment is a non-profit organization charged with the mission to:

  • Educate the public about the disease of opioid addiction and the buprenorphine treatment option.
  • Help reduce the stigma and discrimination associated with patients with addiction disorders.
  • Serve as a conduit connecting patients in need of treatment to qualified treatment providers.

We incorporated as a non-profit corporation in Connecticut April 1, 2005. We have 501(c)3 tax exempt status with the IRS as a charitable organization. Any donations are tax deductible for the year in which the donation was made. We are physically located at 411 Colt Highway, Farmington, CT.

Voluntary Discloser:
Funding for this organization is provided by anonymous donors whose lives were touched by evidence-based addiction treatment and were willing to contribute to the cause. In past years NAABT, Inc. has also asked for and received donations from pharmaceutical companies in the form of  “Unrestricted Educational Grants.” The grants were “unrestricted” so that there were no “strings” attached. NAABT, Inc. has complete control over how funds are used, there are no restrictions on the content or mission of this site, and donors have no control over the content of the site or NAABT’s activities. NAABT, Inc. is solely responsible for all of its activities. We provide a source for educational information, plus a tool for helping patients connect with physicians.

We will strive to remain a non biased, reputable, and accurate source for those seeking information on evidence-based addiction treatments. Buprenorphine is not a cure nor a miracle medication, but a new and effective tool in fighting opioid addiction. Medication is only a small part of a comprehensive recovery plan.

We at NAABT wish you and your loved ones the very best in treatment and in life. Let us know if we can help you further.

Mailing Address:

NAABT, Inc.
P.O. Box 333
Farmington, CT 06034
Fax: 860.269.4391
Click here to send us an email.

This page was last modified on : 02/17/2014

The Purpose of Buprenorphine Treatment:

To suppress the debilitating symptoms of cravings and withdrawal, enabling the patient to engage in therapy, counseling and support, so they can implement positive long-term changes in their lives which develops into the new healthy patterns of behavior necessary to achieve sustained addiction remission. - explain -

The National Alliance of Advocates for Buprenorphine Treatment is a non-profit organization charged with the mission to:

  1. U.S. Food and Drug Administration, FDA Talk Paper, T0238, October 8, 2002, Subutex and Suboxone approved to treat opiate dependence.
  2. Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04-3939. Rockville, Md: Substance Abuse and Mental Health Services Administration, 2004.
  3. Subutex Discontinued in the US market in late 2011.
  4. Zubsolv (bup/nx sublingual tablet) FDA approved 7/3/2013 see buprenorphine pipeline graphic
  5. Bunavail (bup/nx bucal film) FDA approved 6/6/2014 see buprenorphine pipeline graphic
  6. Probuphine Rejected by FDA 4/30/2013 - may resubmit in late 2015 - Probuphine denied by FDA